AstraZeneca (NASDAQ: AZN) reports first-quarter results on Wednesday, with analysts expecting a solid but unexciting print, as investor focus shifts ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Hot List Hot List Pro

AstraZeneca's BREZTRI wins US approval for asthma treatmentApril 28, 2026 7:03 AM BREZTRI approved in the US for asthma as first and only triple therapy for patients 12 years of age and olderApril 28, 2026 7:00 AM AstraZeneca wins FDA approval for SAPHNELO autoinjector pen for lupusApril 27, 2026 7:03 AM SAPHNELO approved in the US for subcutaneous self-administration as a new autoinjector for the treatment of systemic lupus erythematosusApril 27, 2026 7:00 AM